Aclaris Therapeutics (ACRS) Competitors $1.13 +0.01 (+0.89%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. VECT, KALV, AVBP, TRVI, RCKT, PHAR, ANAB, LENZ, OPT, and COGTShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include VectivBio (VECT), KalVista Pharmaceuticals (KALV), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Rocket Pharmaceuticals (RCKT), Pharming Group (PHAR), AnaptysBio (ANAB), LENZ Therapeutics (LENZ), Opthea (OPT), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. VectivBio KalVista Pharmaceuticals ArriVent BioPharma Trevi Therapeutics Rocket Pharmaceuticals Pharming Group AnaptysBio LENZ Therapeutics Opthea Cogent Biosciences Aclaris Therapeutics (NASDAQ:ACRS) and VectivBio (NASDAQ:VECT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking. Do institutionals and insiders hold more shares of ACRS or VECT? 98.3% of Aclaris Therapeutics shares are held by institutional investors. 6.4% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 9.7% of VectivBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, ACRS or VECT? Aclaris Therapeutics has higher earnings, but lower revenue than VectivBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$18.72M6.46-$88.48M-$1.51-0.74VectivBio$27.34M20.97-$93.74MN/AN/A Do analysts rate ACRS or VECT? Aclaris Therapeutics currently has a consensus price target of $11.67, indicating a potential upside of 941.67%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aclaris Therapeutics is more favorable than VectivBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor ACRS or VECT? In the previous week, Aclaris Therapeutics and Aclaris Therapeutics both had 1 articles in the media. Aclaris Therapeutics' average media sentiment score of 1.89 beat VectivBio's score of 0.59 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aclaris Therapeutics Very Positive VectivBio Positive Which has more risk & volatility, ACRS or VECT? Aclaris Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, VectivBio has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Is ACRS or VECT more profitable? VectivBio has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -136.65%. VectivBio's return on equity of 0.00% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-136.65% -40.26% -31.71% VectivBio N/A N/A N/A Does the MarketBeat Community believe in ACRS or VECT? Aclaris Therapeutics received 378 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 66.67% of users gave Aclaris Therapeutics an outperform vote while only 43.48% of users gave VectivBio an outperform vote. CompanyUnderperformOutperformAclaris TherapeuticsOutperform Votes38866.67% Underperform Votes19433.33% VectivBioOutperform Votes1043.48% Underperform Votes1356.52% SummaryAclaris Therapeutics beats VectivBio on 10 of the 16 factors compared between the two stocks. Remove Ads Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$120.87M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-2.156.8121.7017.82Price / Sales6.46225.96377.7294.61Price / CashN/A65.6738.1534.64Price / Book0.505.866.464.00Net Income-$88.48M$141.86M$3.20B$247.23M7 Day Performance-7.44%4.38%2.77%1.44%1 Month Performance-28.21%-12.76%-8.60%-6.26%1 Year Performance-8.20%-11.13%10.40%0.59% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics2.3647 of 5 stars$1.13+0.9%$11.67+932.4%-7.4%$121.95M$18.72M-2.17100Gap DownVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030News CoverageHigh Trading VolumeKALVKalVista Pharmaceuticals4.1872 of 5 stars$11.50+7.4%$24.83+115.9%+2.4%$571.73MN/A-3.16100High Trading VolumeAVBPArriVent BioPharma1.1503 of 5 stars$16.61+1.2%$39.00+134.8%+9.6%$565.01MN/A-6.4640News CoveragePositive NewsGap DownTRVITrevi Therapeutics3.3953 of 5 stars$5.78-4.5%$17.56+203.8%+120.6%$558.82MN/A-13.1420RCKTRocket Pharmaceuticals4.611 of 5 stars$5.19+1.4%$43.00+728.5%-72.8%$553.41MN/A-1.89240Insider TradeNews CoverageHigh Trading VolumePHARPharming Group2.4523 of 5 stars$8.11+5.5%$30.00+269.9%-21.2%$551.73M$297.20M-31.19280Short Interest ↓News CoveragePositive NewsANABAnaptysBio2.5164 of 5 stars$17.78-3.9%$35.11+97.5%-14.9%$545.26M$91.28M-2.92100Gap DownLENZLENZ Therapeutics1.7564 of 5 stars$19.50-7.9%$41.67+113.7%+16.9%$537.09MN/A-4.09110Analyst ForecastNews CoverageGap DownHigh Trading VolumeOPTOpthea0.6782 of 5 stars$3.41+7.2%$1.33-60.9%-4.2%$524.84M$87,666.000.008Gap UpCOGTCogent Biosciences2.0741 of 5 stars$4.58-4.0%$14.43+215.0%-25.1%$521.43MN/A-1.8580News CoverageHigh Trading Volume Remove Ads Related Companies and Tools Related Companies VectivBio Competitors KalVista Pharmaceuticals Competitors ArriVent BioPharma Competitors Trevi Therapeutics Competitors Rocket Pharmaceuticals Competitors Pharming Group Competitors AnaptysBio Competitors LENZ Therapeutics Competitors Opthea Competitors Cogent Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACRS Stock Free ACRS Stock Alerts